BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Amilpar - 2010 Consolidated Revenues Grow by 56% and EBITDA Increases by 64%


3/23/2011 7:49:07 AM

RIO DE JANEIRO, March 22, 2011 /PRNewswire/ -- AMIL PARTICIPACOES S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3.SA), the largest healthcare company in Brazil, announced today its consolidated results for December 31, 2010, in accordance with Brazilian corporate law and the ANS account chart.

HIGHLIGHTS

  • The number of Amil's members increased by +13.3% in 2010, while those of Medial fell by -14.1% due to the contract renegotiations process. Totalconsolidated membership stood at 5,309.7 thousand at the close of 2010, 3.4% up on the end of 2009 and approximately 2.7% more than in 3Q10.
  • Adjusted Operating Revenues totaled R$ 2,058.4 million in 4Q10, 41.4% up year-on-year (with one month of Medial only in 4Q09) and 3.5% more than the previous quarter. Annual revenues came to R$ 7,821.7 million, 56.0% higher than in 2009 (also with only one month of Medial).
  • Adjusted EBITDA amounted to R$ 176.2 million in 4Q10 (8.6% margin), 80.2% or 1.9 p.p. up on 4Q09, and R$ 605.9 million (7.7% margin) in the FY10, a 64.2% increase over the year before, underlining the Company's capacity to turn around Medial's loss-making operation (impacting only one month in 2009).
  • Accounting Net Income totaled R$ 131.7 million in 2010, 27.4% up on the previous year. Based on this amount, was proposed the payment of R$ 40 million in dividends, subject to the Annual Shareholders' Meeting approval.

To access the Earnings Release full version visit our website at www.amilpar.com.br/ir

NEXT EVENTS: CONFERENCE CALLS

ENGLISH

03.23.2011 | 11:00 a.m. Brasília (10:00 a.m. New York)

Phone: +1 (412) 317-6776

Code: Amilpar

Webcast: www.amilpar.com.br/ir


PORTUGUESE

03.23.2011 | 2:00 p.m. Brasília (1:00 p.m. New York)

Phone: +55 (11) 2188-0155

Code: Amilpar

Webcast: www.amilpar.com.br/ri



IR CONTACT

Erwin Kleuser
Investor Relations Officer
Phone: +55 (21) 3805-1155
invest@amil.com.br
www.amilpar.com.br/ir

ABOUT AMILPAR

Amil Participacoes S.A. is the largest managed care organization in Brazil, according to the ANS, currently assisting over 5 million members in the states of Sao Paulo, Rio de Janeiro, Parana, Minas Gerais, Pernambuco, Bahia and in Distrito Federal.

SOURCE Amilpar



Read at BioSpace.com

Amilpar
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES